Investors and Media



Sangamo is a clinical stage biopharmaceutical company focused on the research, development and commercialization of engineered DNA-binding proteins as novel therapeutics to treat unmet medical needs. We are worldwide leaders in developing zinc finger DNA-binding proteins (ZFPs) for therapeutic gene regulation and modification. Our ZFP technology platform has multiple applications in:

  • Human Therapeutics
  • High-value Research Tools
  • Transgenic Animals
  • Cell-line Engineering for Protein Manufacturing
  • Plant Agriculture

View all »   RSSRecent Releases

Oct 16, 2014
Sangamo BioSciences ZFP Therapeutic Program in HIV/AIDS Featured at Three Major Scientific Conferences in October 2014

Oct 15, 2014
Sangamo BioSciences Announces Third Quarter 2014 Conference Call and Webcast


View all »Events & Presentations

Oct 22, 2014 at 5:00 PM ET
Sangamo's Quarterly Teleconference

Stock Quote

Ticker:
SGMO
Exchange:
NASDAQ
Price:
10.70
Change:
+ 0.18
Day High:
10.80
Day Low:
10.43
Volume:
569,400
4:00 PM ET on Oct 20, 2014

Shareholder Tools